Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.42 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 9/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | FCER2 | P06734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319068 | 0.89 | GHSR (0.49) | GHSRBDKRB2TACR1 | |
| SCHEMBL6319064 | 0.89 | GHSR (0.49) | GHSRBDKRB2TACR1 | |
| SCHEMBL8715798 | 0.88 | GHSR (0.41) | GHSRBDKRB2TACR1 | |
| SCHEMBL6316765 | 0.87 | BDKRB2 (0.45) | GHSRBDKRB2TACR1F2FCER2 | |
| SCHEMBL3267249 | 0.78 | GHSR (0.50) | GHSRTACR1 | |
| SCHEMBL3267246 | 0.78 | GHSR (0.50) | GHSRTACR1 | |
| SCHEMBL4427112 | 0.77 | FCER2 (0.53) | GHSRTACR1F2FCER2 | |
| SCHEMBL4426088 | 0.77 | FCER2 (0.53) | GHSRTACR1F2FCER2 | |
| SCHEMBL6317992 | 0.77 | FCER2 (0.53) | GHSRTACR1F2FCER2 | |
| SCHEMBL6319205 | 0.76 | NPY5R (0.49) | GHSRTACR1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | GHSR 2/4885BDKRB2 212/4885TACR1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.